Fisher & Paykel Healthcare Corporation Limited (NZSX:FPH, ASX:FPH) announced today that it intends to release on Thursday 19 November its financial results for the six months ended 30 September 2009. The release will be issued shortly after 9:00am NZDT, 7:00am AEDT (3pm USEST, Wednesday 18 November).
Fisher & Paykel Healthcare will host a conference call to review the results and to discuss the outlook for the remainder of the 2010 financial year. The conference call is scheduled to begin at 10:00am NZDT, 8:00am AEDT (4pm USEST, Wednesday 18 November) and will be broadcast simultaneously over the Internet.
To listen to the webcast access the company’s website at www.fphcare.com. Please allow extra time prior to the webcast to visit the site and download the streaming media software if required. An online archive of the event will be available approximately two hours after the webcast and will remain onsite for two weeks.
To attend the conference call, participants will need to dial in to one of the numbers below at least
5 minutes prior to the scheduled call time and identify yourself to the operator. When prompted, please quote the conference code of: 39555195.
New Zealand Toll Free 0800 446 041
Australia Toll Free 1800 701 269
USA Toll Free 1866 242 1388
International +61 2 882 36760
An audio replay of the conference call will be available approximately 2 hours after the call and will be accessible for two weeks by dialing one of the numbers below. When prompted please enter the conference code of: 39555195.
New Zealand Toll Free 0800 445 136
Australia Toll Free 1800 766 700
USA Toll Free 1866 214 5335
International +61 2 823 55000
About Fisher & Paykel Healthcare
Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and systems for use in respiratory care, acute care and the treatment of obstructive sleep apnea. The company’s products are sold in more than 120 countries worldwide. For more information about the company visit www.fphcare.com
Contact: Michael Daniell MD/CEO on +64 9 574 0161 or Tony Barclay CFO on +64 9 574 0119.
Fisher & Paykel Healthcare to Announce Half Year Results
Find clinical evidence and practice guidelines for delivering nasal high flow (aka HFNC) therapy.
Providing Optimal Humidity for intubated patients
Featuring under nose NIV masks (F&P Visairo) and full face NIV masks - (F&P Nivairo), with vented and non-vented options to suit your hospital NIV mask needs.
Establish effective spontaneous breathing or assist ventilation of the lungs
Respiratory support that replaces spontaneous breathing
Noninvasive respiratory support that provides a continuous distending pressure
Noninvasive respiratory support that delivers high flows of blended air and oxygen
Designed to work in harmony with the way patients naturally breathe while they sleep
F&P SleepStyle - designed to strike the balance between comfort and effective treatment